0001415889-24-012166.txt : 20240503
0001415889-24-012166.hdr.sgml : 20240503
20240503161954
ACCESSION NUMBER: 0001415889-24-012166
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240503
DATE AS OF CHANGE: 20240503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wassil Jim
CENTRAL INDEX KEY: 0001813798
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 24913420
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 353 HATCH DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
form4-05032024_080545.xml
X0508
4
2024-05-01
0001649094
Vaxcyte, Inc.
PCVX
0001813798
Wassil Jim
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
false
true
false
false
CHIEF OPERATING OFFICER
1
Common Stock
2024-05-01
4
S
0
1753
61.227
D
216709
D
Common Stock
2024-05-01
4
S
0
1062
61.993
D
215647
D
Common Stock
2024-05-01
4
S
0
185
63.646
D
215462
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $60.76 to $61.495. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The Reporting Person has entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Since the date of the Reporting Person's ownership report filed on April 19, 2024, the Reporting Person transferred 3,378 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.
The price reported is a weighted-average price. The shares were sold at prices ranging from $61.775 to $62.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $63.37 to $63.905. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-05-03